Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen‐specific immunotherapy in patients with MUC1‐positive advanced cancer
The Journal of Gene Medicine2003Vol. 5(8), pp. 690–699
Citations Over TimeTop 10% of 2003 papers
Christoph Rochlitz, Robert A. Figlin, Patrick Squiban, Marc Salzberg, Miklos Pless, Richard Herrmann, Éric Tartour, Yongxiang Zhao, Nadine Bizouarne, Martine Baudin, Bruce Acres
Abstract
The administration of TG4010 was generally well tolerated in patients with metastatic tumors, and transient disease stabilization was observed in several patients, warranting further clinical studies with the product.
Related Papers
- → Mucin genes have different expression patterns in healthy and diseased upper airway mucosa(2006)108 cited
- → Role of epithelial mucins during airway infection(2011)89 cited
- → Expression of Different Glycoforms of Membrane Mucin(MUC1) and Secretory Mucin (MUC2, MUC5AC and MUC6) in Pancreatic Neoplasms(2003)44 cited
- → Mucins of the eye(1999)1 cited
- → The influence of luteolin on expression of epithelial MUC1 mucin in human skin fibroblasts(2016)